Results 141 to 150 of about 157,713 (224)

End points and clinical trial designs in pulmonary arterial hypertension

, 2004
Marius M. Hoeper, Ronald J. Oudiz, Andrew J. Peacock, Victor F. Tapson, Sheila G. Haworth, Adaani Frost, Adam Torbicki   +6 more
openalex   +1 more source

Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re‐PHIRE

ESC Heart Failure, EarlyView.
Abstract Aims Despite receiving guideline‐directed medical heart failure (HF) therapy, patients with pulmonary hypertension associated with left heart disease (PH‐LHD) experience higher mortality and hospitalization rates than the general HF population.
Marcin Ufnal, Kathleen Connolly, Marcus Millegard, Elena Surkova, Marco Guazzi, Diana Bonderman, Justin Ezekowitz, Finn Gustafsson, Michał Ciurzyński, Raquel López Vilella, Tariq Ahmad, Roy Gardner, Pavel Jansa, Sandra van Wijk, Koichiro Kinugawa, Erik Björklund, Zhi‐Cheng Jing, Stephan Rosenkranz   +17 more
wiley   +1 more source

Pulmonary Arterial Hypertension in a Patient With a Lung Mass: Any Link? [PDF]

Cureus
Alharbi AM, Alqarni MS, Alkahtani AA, Alghamdi B.   +3 more
europepmc   +1 more source

End points for pulmonary arterial hypertension: a way backward [PDF]

, 2004
Sofia Martins, Mauro Maniscalco, Pierluigi Carratù, Onofrio Resta   +3 more
openalex   +1 more source

Genetic cardiomyopathy mimicking isolated cardiac sarcoidosis: Diagnostic challenges with positron emission tomography

ESC Heart Failure, EarlyView.
Daigo Nishijo, Shunsuke Inoue, Zhehao Dai, Seitaro Nomura, Ryo Abe, Takashi Hiruma, Chie Bujo, Tsukasa Oshima, Manami Katoh, Yu Shimizu, Masamichi Ito, Kenichiro Yamagata, Junichi Ishida, Eisuke Amiya, Norifumi Takeda, Katsuhito Fujiu, Masaru Hatano, Hiroyuki Morita, Norihiko Takeda, Issei Komuro   +19 more
wiley   +1 more source

Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti‐cancer agents

ESC Heart Failure, EarlyView.
Abstract Background The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio‐oncology has received increasing attention owing to the cardiotoxic effects of anti‐cancer therapies.
Tomiko Sunaga, Takahiro Okada, Yoshitaka Iso, Mio Ebato, Tsutomu Toshida, Shuichi Nawata, Hiroshi Suzuki, Mari Kogo   +7 more
wiley   +1 more source

Imaging manifestations of hereditary hemorrhagic telangiectasia with pulmonary arterial hypertension: a case report. [PDF]

Front Cardiovasc Med
Qin G, Chen S, Huang F, Mo L, Li K.
europepmc   +1 more source

State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age

ESC Heart Failure, EarlyView.
Abstract Heart failure with preserved ejection fraction (HFpEF) is defined by heart failure (HF) with a left ventricular ejection fraction (LVEF) of at least 50%. HFpEF has a complex and heterogeneous pathophysiology with multiple co‐morbidities contributing to its presentation. Establishing the diagnosis of HFpEF can be challenging.
Roy Rasalam, Andrew Sindone, Gary Deed, Ralph G. Audehm, John J. Atherton   +4 more
wiley   +1 more source

Pediatric Pulmonary Arterial Hypertension; is it Possible to Predict its Outcome? [PDF]

J Saudi Heart Assoc
Agha HM, Hegazy R, Gamal A, Essam R, Elmessih AA, Behairy A, Dahdah N, Abdelwahed A, Sobhy N, Ali N.   +9 more
europepmc   +1 more source

Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension [PDF]

, 2005
M.C. Tamby
openalex   +1 more source